Matches in SemOpenAlex for { <https://semopenalex.org/work/W432981> ?p ?o ?g. }
- W432981 endingPage "29" @default.
- W432981 startingPage "1" @default.
- W432981 abstract "Parkinson’s disease (PD) is characterized by progressive neuronal loss associated with Lewy bodies in many subcortical nuclei leading to multiple biochemical and pathophysiological changes of clinical relevance. Loss of nigral neurons causing striatal dopamine deficiency is related to both the duration and clinical stages (severity) of the disease. The clinical subtypes of PD have different morphological lesion patterns: a) The akinetic-rigid type shows more severe cell loss in the ventrolateral part of substantia nigra zona compacta (SNZC) that projects to the dorsal putamen than the medial part projecting to caudate nucleus and anterior putamen, with negative correlation between SNZC cell counts, severity of akinesia-rigidity, and dopamine loss in the posterior putamen. Reduced dopaminergic input causes overactivity of the GABA ergic inhibitory striatal neurons projecting via the “indirect loop” to SN zona reticulata (SNZR) and medial pallidum (GPI) leading to inhibition of the glutamatergic thalamo-cortical motor loop and reduced cortical activation. b) The tremor-dominant type shows more severe neuron loss in medial than in lateral SNZC and damage to the retrorubral field A8 containing only few tyrosine hydroxylase and dopamine transporter immunoreactive (IR) neurons but mainly calretinin-IR cells. A8 that is rather preserved in rigid-akinetic PD (protective role of calcium-binding protein?) projects to the matrix of dorsolateral striatum and ventromedial thalamus. Together with area A10 it influences the striai efflux via SNZR to thalamus and from there to prefrontal cortex. Rest tremor in PD is associated with increased metabolism in the thalamus, subthalamus, pons, and premotor-cortical network suggesting an increased functional activity of thalamo-motor projections. In essential tremor, no significant pathomorphological changes but overactivity of cerebello-thalamic loop have been observed. c) In the akinetic-rigid forms of multisystem atrophy, degeneration is more severe in the lateral SNZC with severe loss of calbindin-IR cells reflecting initial degeneration of the striatal matrix in the caudal putamen with transsynaptic degeneration of striatonigral efferences that remain intact in PD. This fact and loss of striatal D2 receptors — as in advanced stages of PD — are reasons for negative response to L-dopa substitution. These data suggest different pathophysiological mechanisms of the clinical subtypes of PD that have important therapeutic implications. d) Involvement of extranigral structures in PD includes the mesocortical dopaminergic system, the noradrenergic locus coeruleus, dorsal vagal nucleus and medullary nuclei, serotonergic dorsal raphe, nucleus basalis of Meynert and other cholinergic brainstem nuclei, e.g. Westphal-Edinger nucleus (controlling pupillomotor function), posterolateral hypothalamus and the limbic system, e.g. amygdaloid nucleus, part of hippocampal formation, limbic thalamic nuclei with prefrontal projections, etc. Damage to multiple neuronal systems by the progressing degenerative process causing complex biochemical changes may explain the variable clinical picture of PD including vegetative, behavioural and cognitive dysfunctions, depression, pharmacotoxic psychoses, etc. Future comparative clinico-morphological and pathobiochemical studies will further elucidate the pathophysiological basis of specific clinical symptoms of PD and related disorders providing a broader basis for effective treatment strategies. Parkinson’s disease (PD) is characterized by progressive degeneration of the nigrostriatal dopaminergic system and other subcortical neuronal systems leading to striatal dopamine deficiency and other biochemical deficits related to the variable clinical signs and symptoms of the disorder. While the pathogenesis and aetiology of PD are still unknown, the recent elucidation of the morphological and pathophysiological substrates of several clinical dysfunctions in PD has provided a better insight into the course of the disease and important implications for treatment (Jellinger, 1998)." @default.
- W432981 created "2016-06-24" @default.
- W432981 creator A5042083351 @default.
- W432981 date "1999-01-01" @default.
- W432981 modified "2023-10-05" @default.
- W432981 title "Post mortem studies in Parkinson’s disease — is it possible to detect brain areas for specific symptoms?" @default.
- W432981 cites W1502768627 @default.
- W432981 cites W1527671059 @default.
- W432981 cites W1546941611 @default.
- W432981 cites W18675733 @default.
- W432981 cites W189025964 @default.
- W432981 cites W1931999809 @default.
- W432981 cites W1965762855 @default.
- W432981 cites W1965866489 @default.
- W432981 cites W1969280474 @default.
- W432981 cites W1972570427 @default.
- W432981 cites W1972781961 @default.
- W432981 cites W1976749972 @default.
- W432981 cites W1977430596 @default.
- W432981 cites W1978318953 @default.
- W432981 cites W1979786583 @default.
- W432981 cites W1980065838 @default.
- W432981 cites W1980493562 @default.
- W432981 cites W1983383694 @default.
- W432981 cites W1983721061 @default.
- W432981 cites W1986042913 @default.
- W432981 cites W1986776141 @default.
- W432981 cites W1993275163 @default.
- W432981 cites W1994761650 @default.
- W432981 cites W1995545205 @default.
- W432981 cites W1995684956 @default.
- W432981 cites W1996046462 @default.
- W432981 cites W1999667056 @default.
- W432981 cites W2000921610 @default.
- W432981 cites W2002060278 @default.
- W432981 cites W2004272659 @default.
- W432981 cites W2004335540 @default.
- W432981 cites W2004678974 @default.
- W432981 cites W2005160511 @default.
- W432981 cites W2005890826 @default.
- W432981 cites W2006497054 @default.
- W432981 cites W2008028794 @default.
- W432981 cites W2011775843 @default.
- W432981 cites W2011850283 @default.
- W432981 cites W2012306356 @default.
- W432981 cites W2012871568 @default.
- W432981 cites W201467903 @default.
- W432981 cites W2015298048 @default.
- W432981 cites W2016131473 @default.
- W432981 cites W2016703884 @default.
- W432981 cites W2016901254 @default.
- W432981 cites W2018244586 @default.
- W432981 cites W2019384585 @default.
- W432981 cites W2022170924 @default.
- W432981 cites W2022976503 @default.
- W432981 cites W2024317187 @default.
- W432981 cites W2032139930 @default.
- W432981 cites W2032190306 @default.
- W432981 cites W2032777075 @default.
- W432981 cites W2033289442 @default.
- W432981 cites W2034210468 @default.
- W432981 cites W2038887346 @default.
- W432981 cites W2039130139 @default.
- W432981 cites W2039194913 @default.
- W432981 cites W2040451117 @default.
- W432981 cites W2042348810 @default.
- W432981 cites W2043126301 @default.
- W432981 cites W2047651812 @default.
- W432981 cites W2048433944 @default.
- W432981 cites W2050786534 @default.
- W432981 cites W2052373532 @default.
- W432981 cites W2052492316 @default.
- W432981 cites W2053124094 @default.
- W432981 cites W2054421268 @default.
- W432981 cites W2054543891 @default.
- W432981 cites W2054848243 @default.
- W432981 cites W2056798863 @default.
- W432981 cites W2056956417 @default.
- W432981 cites W2057501370 @default.
- W432981 cites W2057607692 @default.
- W432981 cites W2058332607 @default.
- W432981 cites W2058396154 @default.
- W432981 cites W2058691511 @default.
- W432981 cites W2059977837 @default.
- W432981 cites W2061278130 @default.
- W432981 cites W2061538829 @default.
- W432981 cites W2061768322 @default.
- W432981 cites W2064247269 @default.
- W432981 cites W2065447025 @default.
- W432981 cites W2065617745 @default.
- W432981 cites W2067132930 @default.
- W432981 cites W2067487290 @default.
- W432981 cites W2067945948 @default.
- W432981 cites W2068093530 @default.
- W432981 cites W2068225967 @default.
- W432981 cites W2068829020 @default.
- W432981 cites W2069304323 @default.
- W432981 cites W2069550409 @default.